MET (Ab-1313) Antibody

What is MET (Ab-1313) Antibody and what biological target does it recognize?

MET (Ab-1313) Antibody is a rabbit polyclonal antibody that specifically recognizes endogenous levels of total MET protein (also known as hepatocyte growth factor receptor or c-Met). It was developed using a synthesized peptide derived from the internal region of human MET . The antibody targets MET, a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor (HGF). MET regulates critical physiological processes including cell proliferation, scattering, morphogenesis, and survival .

What are the validated applications for MET (Ab-1313) Antibody and appropriate working dilutions?

The primary validated applications for MET (Ab-1313) Antibody include:

Experimental validation has been demonstrated in human cell lines including JK cells and K562 cells . When performing Western blot analysis, the antibody successfully detects endogenous levels of MET protein at the expected molecular weight .

How should MET (Ab-1313) Antibody be stored and handled to maintain optimal activity?

For optimal activity preservation:

• Store at -20°C in the provided buffer (rabbit IgG in phosphate buffered saline without Mg²⁺ and Ca²⁺, pH 7.4, containing 150mM NaCl, 0.02% sodium azide and 50% glycerol)

• Avoid repeated freeze-thaw cycles by making single-use aliquots

• Allow the antibody to reach room temperature before opening

• Centrifuge the vial briefly before use to collect all material at the bottom

• Working dilutions should be prepared fresh and used within 24 hours

How should researchers design Western blot experiments using MET (Ab-1313) Antibody?

When designing Western blot experiments with MET (Ab-1313) Antibody:

• Sample preparation: Prepare cell or tissue lysates using standard protocols with protease inhibitors

• Protein loading: Load 20-50 μg of total protein per lane

• Electrophoresis conditions: Use 8-10% SDS-PAGE gels (MET is approximately 145 kDa)

• Transfer conditions: Transfer to PVDF or nitrocellulose membranes

• Blocking: Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody incubation: Dilute MET (Ab-1313) Antibody at 1:500-1:3000 in blocking buffer and incubate overnight at 4°C

• Secondary antibody: Use anti-rabbit IgG conjugated to HRP at 1:5000-1:10000

• Detection: Use enhanced chemiluminescence (ECL) detection reagents

Expected results: A specific band at approximately 145 kDa corresponding to MET protein, as validated in JK cells and K562 cells .

What are effective validation strategies to confirm MET (Ab-1313) Antibody specificity?

To validate antibody specificity:

• Peptide competition assay: Pre-incubate the antibody with excess synthesized peptide immunogen before applying to Western blot or other applications. This should abolish specific binding, as demonstrated in published results

• Positive and negative controls:

  • Positive controls: Cell lines known to express MET (such as JK cells and K562 cells)

  • Negative controls: Cell lines with low or no MET expression, or MET knockout cell lines

• siRNA knockdown: Compare antibody signal between wild-type cells and cells treated with MET-specific siRNA

• Multiple detection methods: Confirm results using alternative techniques (e.g., IF, IHC) or a different antibody against MET

How can MET (Ab-1313) Antibody be utilized in MET signaling pathway research?

MET (Ab-1313) Antibody can be employed in several advanced applications for MET signaling research:

• Signaling cascade analysis: Monitor total MET levels while studying downstream signaling effects through RAS-ERK, PI3K-AKT, and PLCγ-PKC pathways in response to HGF stimulation or drug treatments

• Correlation with phosphorylation states: Use in conjunction with phospho-specific MET antibodies to establish the relationship between total MET levels and activation status

• Protein-protein interaction studies: Use in co-immunoprecipitation experiments to examine MET interactions with downstream effectors like PI3K subunit PIK3R1, PLCG1, SRC, GRB2, STAT3, or the adapter GAB1

• MET degradation and trafficking studies: Monitor changes in total MET levels during receptor internalization, recycling, and degradation experiments

Example research workflow:

• Serum-starve cells overnight

• Treat with HGF (20-50 ng/mL) for various time points (0, 5, 15, 30, 60 min)

• Lyse cells and perform Western blot for total MET using MET (Ab-1313) Antibody

• Strip and reprobe for phospho-MET and downstream signaling molecules

What methodological approaches can be used to study MET (Ab-1313) Antibody in live cell binding assays?

For live cell binding assays with MET (Ab-1313) Antibody:

• Protocol design:

  • Seed cells at 1×10⁶ cells per well in appropriate medium

  • Allow cells to reach 80-90% confluence after 24 hours

  • Change medium to pre-warmed DMEM (pH 7.4 at 37°C) 1 hour prior to binding experiment

  • For blocking experiments, add 50X excess of unlabeled antibody 20 minutes before adding labeled antibody

  • Add labeled antibody (can be fluorescently labeled or radiolabeled)

  • Incubate at 37°C with CO₂ for 1 hour

  • Wash cells with ice-cold buffer multiple times

  • For extraction, add lysis buffer (1% SDS, 10mM sodium borate)

  • Analyze binding through appropriate detection methods

• Controls and variables to consider:

  • Positive control: MET-overexpressing cells

  • Negative control: MET knockout cells

  • Competition assay with unlabeled antibody

  • Temperature dependency (4°C vs. 37°C)

  • Time course analysis (15, 30, 60, 120 min)

How does MET (Ab-1313) Antibody compare with biparatopic MET antibodies in research applications?

When comparing MET (Ab-1313) Antibody (a conventional antibody) with biparatopic MET antibodies:

• Mechanistic differences:

  • MET (Ab-1313) Antibody: Recognizes a single epitope in the internal region of MET protein

  • Biparatopic antibodies: Recognize two distinct epitopes in the MET Sema domain, leading to enhanced MET degradation through inhibition of recycling and promoting lysosomal trafficking

• Functional comparison:

  • Traditional antibodies like MET (Ab-1313): Useful for detection and quantification of total MET protein

  • Biparatopic antibodies: Show significantly better activity in MET-driven tumor models than either parental antibodies or their mixture, with potential therapeutic applications

• Research applications:

  • MET (Ab-1313): Optimal for monitoring total MET levels in signaling studies, protein expression analysis, and as a control in therapeutic studies

  • Biparatopic antibodies: Better suited for studies focused on MET trafficking, degradation, and therapeutic intervention

Research has shown that biparatopic antibodies induce very transient downstream signaling and fail to activate MET-dependent biological responses, in contrast to conventional antibodies that may have variable effects on signaling .

What are common technical challenges when using MET (Ab-1313) Antibody and how can they be addressed?

For method-specific optimization:

• Ensure complete denaturation of samples for MET detection (heat at 95°C for 5 min in sample buffer)

• For detecting membrane-associated MET, consider using specialized lysis buffers containing 1% Triton X-100 or NP-40

• Phosphatase inhibitors should be included when studying MET in the context of signaling pathway activation

How can researchers distinguish between MET isoforms or processed forms using MET (Ab-1313) Antibody?

MET processing generates multiple molecular forms that can be detected using appropriate techniques:

• Full-length MET vs. cleaved products:

  • Full-length MET: ~145 kDa precursor and ~170 kDa mature form (glycosylated)

  • Alpha chain: ~50 kDa (after furin cleavage)

  • Beta chain: ~145 kDa (after furin cleavage)

  • MET cytoplasmic fragment: ~60 kDa (after gamma-secretase processing)

• Optimization strategies:

  • Use gradient gels (4-15%) to better separate different MET forms

  • Include protease inhibitors in lysis buffer to prevent artificial processing

  • Compare results with domain-specific antibodies targeting different regions of MET

  • Perform immunoprecipitation followed by Western blot to enrich for specific forms

• Experimental design:

  • Induce MET cleavage with PMA treatment (100 nM, 30 min) to generate the cytoplasmic fragment

  • Use selective protease inhibitors to block specific processing steps

  • Compare MET forms in different cellular compartments using subcellular fractionation

How can MET (Ab-1313) Antibody be utilized in antibody-drug conjugate (ADC) research?

MET (Ab-1313) Antibody can support ADC research in several ways:

• Target validation and expression profiling:

  • Quantify MET expression levels across various cancer cell lines and patient-derived samples

  • Correlate expression with potential sensitivity to MET-targeting ADCs

  • Validate MET expression in xenograft models prior to ADC testing

• Mechanism of action studies:

  • Monitor changes in total MET levels after ADC treatment

  • Investigate receptor internalization and trafficking using immunofluorescence approaches

  • Study resistance mechanisms by comparing MET levels before and after acquired resistance

• Complementary research with therapeutic antibodies:

  • Use alongside therapeutic anti-MET antibodies to understand differences in epitope targeting

  • Study binding competition between therapeutic antibodies and MET (Ab-1313)

  • Validate ADC specificity by comparing binding patterns with MET (Ab-1313)

Research indicates that ideal ADC antibody components should facilitate effective internalization, have high antigen affinity, and demonstrate low immunogenicity . MET (Ab-1313) Antibody can serve as a tool in evaluating these properties for MET-targeting ADCs.

What considerations are important when using MET (Ab-1313) Antibody in studies of MET trafficking and degradation?

When studying MET trafficking and degradation:

• Experimental design considerations:

  • Time-course experiments: Monitor MET levels at multiple time points (0, 15, 30, 60, 120 min, 4, 8, 24 hr) after stimulation with HGF

  • Inhibitor studies: Use lysosomal inhibitors (chloroquine, bafilomycin A1) or proteasomal inhibitors (MG132, bortezomib) to distinguish between degradation pathways

  • Subcellular fractionation: Separate membrane, cytosolic, and nuclear fractions to track MET localization

  • Live-cell imaging: Combine with fluorescently tagged MET constructs to complement antibody-based detection methods

• Technical protocol optimization:

  • Include both detergent-soluble and -insoluble fractions in analysis

  • Use gentle lysis conditions to preserve protein-protein interactions

  • Consider pulse-chase experiments with biotinylation to track specific populations of MET

  • Compare results between total MET detection (using MET Ab-1313) and phospho-specific MET antibodies

• Research findings context:
  Research has shown that biparatopic antibodies can inhibit MET recycling, promoting lysosomal trafficking and degradation of MET, whereas conventional antibodies may have different effects on trafficking . MET (Ab-1313) can serve as a valuable tool to quantify these changes in total MET levels.

How can MET (Ab-1313) Antibody contribute to understanding cross-reactivity in antibody-based therapeutics research?

In the context of cross-reactivity research:

• Epitope mapping and cross-reactivity assessment:

  • Use MET (Ab-1313) Antibody alongside therapeutic antibodies to understand epitope overlap

  • Compare binding patterns across different species and MET mutants

  • Identify potential cross-reactive antigens through immunoprecipitation followed by mass spectrometry

• Applications in disease research:

  • Recent studies have identified cross-reactivity between EBV-specific antibodies and human proteins in multiple sclerosis

  • Similar methodologies could be applied to investigate potential cross-reactivity of MET-targeting antibodies with other RTKs or related proteins

  • This approach is particularly relevant for assessing off-target effects of therapeutic antibodies

• Methodological approach:

  • Competitive binding assays between MET (Ab-1313) and therapeutic antibodies

  • Sequential immunoprecipitation experiments to identify shared binding targets

  • Protein array screening to systematically assess cross-reactivity

  • Validation through site-directed mutagenesis of potential epitopes